MedTrace Logo

ARUA-ALZ - Connecting Audio and Radio SensingmSystems to Improve Care at Home for ADRD

NCT06170528 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-08-23

No results posted yet for this study

Summary

The purpose of this study is to address the unmet care needs and reduce the care burdens for persons with ADRD (Alzheimer's Disease and Alzheimer's Disease Related Dementias) and their caregivers by providing monitoring of daily activities and gestures using audio and radio sensing, providing voice-based reminders intervention.

In phase 1, dyads will participate in two focus groups will take 60 minutes per each. In Phase 2, AURA\_ALZ (connecting Audio and Radio Sensing Systems-Alzheimer's Disease) will deployed for two weeks at participants' home. At the end of the two weeks, usability, acceptability of the use of the system will be measured.

Conditions

  • Alzheimer Disease
  • Caregiver Burden

Interventions

DEVICE

AURA_ALZ

AURA\_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA\_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • The University of Texas Health Science Center at San Antonio

    collaborator OTHER

  • Florida State University

    lead OTHER

Principal Investigators

  • Jing Wang, PhD · Florida State University

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-16
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06170528 on ClinicalTrials.gov